FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  STANKOVICH THOMAS						2. Issuer Name and Ticker or Trading Symbol ReShape Lifesciences Inc. [ RSLS ]								(Chec	k all app Direc	,	ng Pei	rson(s) to Is 10% O Other (	wner
(Last) (First) (Middle) 1001 CALLE AMANECER						3. Date of Earliest Transaction (Month/Day/Year) 08/20/2021								X	below			below)	Specify
(Street) SAN CLEME	SAN CLEMENTE CA 92673				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line)	·				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Execution Date,			3. 4. Securities Transaction Disposed O Code (Instr. 8) 5)						5. Amo Securit Benefic Owned Report	ties For cially (D) Following (I) (		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) (D)	or P	rice	Transaction(s) (Instr. 3 and 4)				(11150.4)
Common Stock, \$0.001 par value per share 08/20/20					.021				P		15,000	A	\$	3.219	17,613			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execu ty or Exercise (Month/Day/Year) if any		if any	on Date,   Transact   Code (In   8)			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				ate	7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)  Amou or Numb of Title Share:		De Se (In	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

**Explanation of Responses:** 

/s/ Thomas Stankovich

08/24/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.